Willmot Mark, Gibson Claire, Gray Laura, Murphy Sean, Bath Philip
Institute of Neuroscience, University of Nottingham, Nottingham NG7 2UK, UK.
Free Radic Biol Med. 2005 Aug 1;39(3):412-25. doi: 10.1016/j.freeradbiomed.2005.03.028. Epub 2005 Apr 12.
Nitric oxide produced by the neuronal or inducible isoform of nitric oxide synthase (nNOS, iNOS) is detrimental in acute ischemic stroke (IS), whereas that derived from the endothelial isoform is beneficial. However, experimental studies with nitric oxide synthase inhibitors have given conflicting results. Relevant studies were found from searches of EMBASE, PubMed, and reference lists; of 456 references found, 73 studies involving 2321 animals were included. Data on the effects of NOS inhibition on lesion volume (mm3, %) and cerebral blood flow (CBF; %, ml * min(-1) * g(-1)) were analyzed using the Cochrane Review Manager software. NOS inhibitors reduced total infarct volume in models of permanent (standardized mean difference (SMD) -0.56, 95% confidence interval (95% CI) -0.86, -0.26) and transient (SMD -0.99, 95% CI -1.25, -0.72) ischemia. Cortical CBF was reduced in models of permanent but not transient ischemia. When assessed by type of inhibitor, total lesion volume was reduced in permanent models by nNOS and iNOS inhibitors, but not by nonselective inhibitors. All types of NOS inhibitors reduced infarct volume in transient models. NOS inhibition may have negative effects on CBF but further studies are required. Selective nNOS and iNOS inhibitors are candidate treatments for acute IS.
由神经元型或诱导型一氧化氮合酶(nNOS、iNOS)产生的一氧化氮在急性缺血性卒中(IS)中具有损害作用,而内皮型一氧化氮合酶产生的一氧化氮则有益。然而,一氧化氮合酶抑制剂的实验研究结果相互矛盾。通过检索EMBASE、PubMed及参考文献列表找到相关研究;在找到的456篇参考文献中,纳入了73项涉及2321只动物的研究。使用Cochrane系统评价管理器软件分析一氧化氮合酶抑制对梗死体积(mm³,%)和脑血流量(CBF;%,ml·min⁻¹·g⁻¹)影响的数据。一氧化氮合酶抑制剂在永久性(标准化均数差(SMD)-0.56,95%置信区间(95%CI)-0.86,-0.26)和短暂性(SMD -0.99,95%CI -1.25,-0.72)缺血模型中可减少总梗死体积。在永久性缺血模型中皮质脑血流量降低,但在短暂性缺血模型中未降低。按抑制剂类型评估时,nNOS和iNOS抑制剂可使永久性模型中的总损伤体积减小,但非选择性抑制剂则不能。所有类型的一氧化氮合酶抑制剂均可使短暂性模型中的梗死体积减小。一氧化氮合酶抑制可能对脑血流量有负面影响,但需要进一步研究。选择性nNOS和iNOS抑制剂是急性缺血性卒中的候选治疗方法。